Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
MEOBF's Cash to Debt is ranked higher than
91% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. MEOBF: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MEOBF' s Cash to Debt Range Over the Past 10 Years
Min: No Debt  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.60
MEOBF's Equity to Asset is ranked lower than
59% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. MEOBF: 0.60 )
Ranked among companies with meaningful Equity to Asset only.
MEOBF' s Equity to Asset Range Over the Past 10 Years
Min: 0.6  Med: 0.68 Max: 0.97
Current: 0.6
0.6
0.97
F-Score: 3
Z-Score: 0.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -639.09
MEOBF's Operating margin (%) is ranked lower than
74% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. MEOBF: -639.09 )
Ranked among companies with meaningful Operating margin (%) only.
MEOBF' s Operating margin (%) Range Over the Past 10 Years
Min: -39225  Med: -593.01 Max: 2.77
Current: -639.09
-39225
2.77
Net-margin (%) -582.77
MEOBF's Net-margin (%) is ranked lower than
73% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. MEOBF: -582.77 )
Ranked among companies with meaningful Net-margin (%) only.
MEOBF' s Net-margin (%) Range Over the Past 10 Years
Min: -29639.29  Med: -493.35 Max: 307.32
Current: -582.77
-29639.29
307.32
ROE (%) -20.28
MEOBF's ROE (%) is ranked higher than
58% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. MEOBF: -20.28 )
Ranked among companies with meaningful ROE (%) only.
MEOBF' s ROE (%) Range Over the Past 10 Years
Min: -53.7  Med: -31.63 Max: 32.72
Current: -20.28
-53.7
32.72
ROA (%) -12.43
MEOBF's ROA (%) is ranked higher than
63% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. MEOBF: -12.43 )
Ranked among companies with meaningful ROA (%) only.
MEOBF' s ROA (%) Range Over the Past 10 Years
Min: -46.4  Med: -26.75 Max: 22.57
Current: -12.43
-46.4
22.57
ROC (Joel Greenblatt) (%) -26.54
MEOBF's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. MEOBF: -26.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MEOBF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -24812.12  Med: -4835.79 Max: 22123.74
Current: -26.54
-24812.12
22123.74
Revenue Growth (3Y)(%) -15.70
MEOBF's Revenue Growth (3Y)(%) is ranked lower than
68% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. MEOBF: -15.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MEOBF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: -15.7
Current: -15.7
EBITDA Growth (3Y)(%) 24.70
MEOBF's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. MEOBF: 24.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MEOBF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 15.60 Max: 65.1
Current: 24.7
0
65.1
EPS Growth (3Y)(%) 13.90
MEOBF's EPS Growth (3Y)(%) is ranked higher than
72% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. MEOBF: 13.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MEOBF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 13.90 Max: 61.2
Current: 13.9
0
61.2
» MEOBF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MEOBF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.69
MEOBF's P/B is ranked higher than
95% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. MEOBF: 0.69 )
Ranked among companies with meaningful P/B only.
MEOBF' s P/B Range Over the Past 10 Years
Min: 0.69  Med: 4.05 Max: 48.95
Current: 0.69
0.69
48.95
P/S 17.64
MEOBF's P/S is ranked lower than
68% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 9.03 vs. MEOBF: 17.64 )
Ranked among companies with meaningful P/S only.
MEOBF' s P/S Range Over the Past 10 Years
Min: 17.64  Med: 84.40 Max: 930
Current: 17.64
17.64
930
Current Ratio 2.53
MEOBF's Current Ratio is ranked lower than
67% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. MEOBF: 2.53 )
Ranked among companies with meaningful Current Ratio only.
MEOBF' s Current Ratio Range Over the Past 10 Years
Min: 1.82  Med: 6.76 Max: 21
Current: 2.53
1.82
21
Quick Ratio 2.53
MEOBF's Quick Ratio is ranked lower than
64% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. MEOBF: 2.53 )
Ranked among companies with meaningful Quick Ratio only.
MEOBF' s Quick Ratio Range Over the Past 10 Years
Min: 1.82  Med: 6.76 Max: 21
Current: 2.53
1.82
21
Days Sales Outstanding 92.16
MEOBF's Days Sales Outstanding is ranked lower than
67% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. MEOBF: 92.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
MEOBF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.01  Med: 140.67 Max: 1147.14
Current: 92.16
26.01
1147.14

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.27
MEOBF's Price/Projected FCF is ranked higher than
78% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 2.91 vs. MEOBF: 1.27 )
Ranked among companies with meaningful Price/Projected FCF only.
MEOBF' s Price/Projected FCF Range Over the Past 10 Years
Min: 3.66  Med: 4.62 Max: 31.33
Current: 1.27
3.66
31.33
Price/Median PS Value 0.23
MEOBF's Price/Median PS Value is ranked higher than
90% of the 846 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. MEOBF: 0.23 )
Ranked among companies with meaningful Price/Median PS Value only.
MEOBF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.73  Med: 0.91 Max: 2.38
Current: 0.23
0.73
2.38
Earnings Yield (Greenblatt) (%) -42.91
MEOBF's Earnings Yield (Greenblatt) (%) is ranked lower than
76% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. MEOBF: -42.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MEOBF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -42.91  Med: 6.20 Max: 7.8
Current: -42.91
-42.91
7.8

More Statistics

Revenue(Mil) $15
EPS $ -0.29
Beta1.65
Short Percentage of Float0.00%
52-Week Range $0.80 - 3.50
Shares Outstanding(Mil)380.10

Analyst Estimate

Jun16 Jun17 Jun18
Revenue(Mil) 20 20 19
EPS($) -0.29 -0.25 -0.23
EPS without NRI($) -0.29 -0.25 -0.23

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:MSB.Australia, LWB.Germany, MESO.USA,
Mesoblast Ltd is an Australian biotechnology company formed in 2004. The Company is engaged in the development, manufacturing and commercialization of biological products for the field of regenerative medicine. Its products are for cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions. The Company and Teva Pharmaceutical Industries Ltd., have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK